北京市HBV感染不同结局患者费用调查

基础医学与临床 ›› 2014, Vol. 34 ›› Issue (9): 1235-1240.

北京市HBV感染不同结局患者费用调查

李雁¹,王怀²,张卫²,王艳红³,段钟平¹,李辉³,王丽³

1. 首都医科大学附属北京佑安医院
2. 北京市疾病预防控制中心
3. 中国医学科学院基础医学研究所

收稿日期:2014-04-17 修回日期:2014-07-09 出版日期:2014-09-05 发布日期:2014-09-02
通讯作者: 王丽 E-mail:wangli0528@vip.sina.com
基金资助:
艾滋病和病毒性肝炎等重大传染病防治科技重大专项

Investigation on the cost of patients with different outcomes related to hepatitis B virus infection in Beijing

Received:2014-04-17 Revised:2014-07-09 Online:2014-09-05 Published:2014-09-02
Contact: Li ZHANG E-mail:wangli0528@vip.sina.com

摘要/Abstract

摘要： 目的了解北京市乙肝感染不同结局者治疗现状及年均总费用，为进一步完善北京市乙肝防治策略提供卫生经济学证据。方法以人群为基础的多阶段抽样和医院为基础的乙肝病例随机抽样相结合的方法，收集乙肝病毒（HBV）感染不同结局相关病例1 587例，调查其2009-07-01 – 2010-06-30因乙肝相关费用。结果共收集急性乙型肝炎89例、乙肝病毒携带者274例、慢性乙型肝炎973例、肝硬化139例、肝癌112例。2/3的慢性乙型肝炎患者在过去的1年中接受过治疗。人均总费用分别为：急性乙型肝炎22 941.68元、乙肝病毒携带者1 007.90元、慢性乙型肝炎11 777.28元、肝硬化54 473.94元和肝癌128 309.35元。肝硬化及肝癌患者年均总费用为当年人均可支配收入的2.04倍和4.80倍。1/3的慢性乙型肝炎患者从未接受过抗病毒治疗。结论北京市乙肝相关疾病，尤其是肝硬化和肝癌给患者造成较大经济负担；慢性乙型肝炎患者的抗病毒治疗率有待进一步提高。

关键词: 乙型肝炎, 经济负担, 直接费用, 间接费用

Abstract: Objective To understand the economic burden for the patients with hepatitis B virus infection in Beijing and to provide health economic evidence for hepatitis B (HB) control. Methods A community-based household survey combined with a hospital-based sampling investigation was used to collect the annual cost of the patients with acute HB, HBsAg carrier, chronic HB, cirrhosis and hepatocellular carcinoma (HCC). Results A total of 1587 HBV infection-related cases were enrolled, including 89 acute HB, 274 HB carrier, 973 chronic HB, 139 cirrhosis, and 112 HCC. The average annual total cost in 2009 was: acute HB, ￥22941.68；HBV carrier, ￥1007.90; chronic HB, ￥11777.28; cirrhosis, ￥54473.94 and HCC, ￥128309.35. The average annual total cost for cirrhosis and HCC patients was 2.03 and 4.80 times higher than annual per capita income, respectively. One-third of patients with chronic HB have never been treated with antivirals. Conclusion HBV related infection has brought great economic burden to the patients, especially cirrhosis and HCC. Anti-viral treatment rate in chronic HB patients should be improved in the future.

Key words: Hepatitis B, Disease burden, Direct cost, Indirect cost

李雁王怀张卫王艳红段钟平李辉王丽. 北京市HBV感染不同结局患者费用调查[J]. 基础医学与临床, 2014, 34(9): 1235-1240.

[1]	王东生杜琴刘彦信张国元郑德先. 慢性乙型肝炎患者血清中sICOS和sPD-1升高及意义[J]. 基础医学与临床, 2015, 35(7): 916-920.
[2]	马磊贾奇男张俊易青青贺建峰张琪. 一种基于计算机的单核苷酸多态性位点检测方法[J]. 基础医学与临床, 2014, 34(2): 229-234.
[3]	王鹏朱争艳李成龙骆莹张海鹏刘辉. EphA2在不同肝癌细胞系中过表达及其与乙肝病毒感染相关[J]. 基础医学与临床, 2013, 33(12): 1590-1594.
[4]	邓益斌张梁王燕菲. HBV S基因反义锁核酸抑制病毒体外复制[J]. 基础医学与临床, 2010, 30(4): 360-363.